Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 February, 2018 12:51 IST
Aurobindo Pharma gets USFDA nod for anti-cough tablets
Source: IRIS | 21 Mar, 2017, 09.14AM
Comments  |  Post Comment

Aurobindo Pharma announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets, 600/30 mg and 1200/60mg (OTC). Aurobindo's Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets are the AB rated generic equivalent of Reckitt Benckiser's Mucinex DM tablets. The product will be launched in Q1FY18.

Guaifenesin and Dextromethorphan Hydrobromide extended-release tablets helps loosen mucus and phlegm, and thin out bronchial secretions, making coughs more productive. The approved product has an estimated market size of US$ 235 million for the twelve months ending December 2016 according to IRI database.

This is the 106 th ANDA (including 21 tentative approvals) approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products. Aurobindo now has a total of 311 ANDA approvals (272 Final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.

Shares of the company gained Rs 1.7, or 0.24%, to trade at Rs 704.90. The total volume of shares traded was 0 at the BSE (9.01 a.m., Tuesday).



Aurobindo Pharma Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Suven Life Sciences secures product patents in India and South Korea - 20-Feb-2018 10:47
IndusInd Bank intimates of no direct credit exposure to Nirav Modi - 20-Feb-2018 09:58
JSW Energy enters into MoU with Govt of Maharashtra - 20-Feb-2018 09:53
Subex partners with Pod Solution - 20-Feb-2018 09:49
Glenmark Pharma presents findings from Phase 2a study of GBR 830 - 19-Feb-2018 10:10
L&T Construction secures order worth Rs 16.80 bn - 19-Feb-2018 09:52
BHEL commissions 18 MW hydro-electric project in Punjab - 16-Feb-2018 13:33
Reliance Communication update on asset monetization - 16-Feb-2018 12:06
8K Miles Software launches blockchain platform 8K Health Edge - 16-Feb-2018 10:16
Mahindra Group to invest Rs 1.76 bn in Zoomcar - 16-Feb-2018 10:06
Larsen & Toubro bags orders worth Rs 15.85 bn - 15-Feb-2018 13:11
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer